Technical Analysis for CBLI - Cleveland BioLabs, Inc.

Grade Last Price % Change Price Change
D 4.67 -7.16% -0.36
CBLI closed down 7.16 percent on Tuesday, April 20, 2021, on 43 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical CBLI trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Gapped Down Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Centerline Cross Bearish -7.16%
Older End-of-Day Signals for CBLI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Lower Bollinger Band Support about 12 hours ago
60 Minute Opening Range Breakdown about 13 hours ago
Down 5% about 13 hours ago
Fell Below Lower Bollinger Band about 13 hours ago
Down 3% about 14 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cleveland BioLabs, Inc. Description

Cleveland BioLabs, Inc., a clinical-stage biotechnology company, engages in the research, development, and commercialization of products that have the potential to treat cancer, reduce death from total body irradiation, and counteract the genotoxic effects of radio- and chemotherapies for oncology patients. Its lead drug is Entolimod, which is being developed for radiation countermeasure and cancer treatment. The company's products candidates also include CBL0102, which is undergoing a Phase I safety and tolerability study in patients with liver metastases of solid tumors of epithelial origin, or primary advanced hepatic carcinoma; and CBL0137, which is in multi-center, single agent, dose escalation Phase I study of the oral formulation in subjects with advanced solid tumors. In addition, it has pre-clinical stage products candidates, such as CBLB612, an inducer and mobilizer of hematopoietic stem cells; Revercom, a cancer drug candidate comprising a liposome-packaged proprietary small molecule named Reversan; Mobilan, a nanoparticle-formulated recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand, flagellin; Arkil, a prospective treatment for prostate cancer; Antimycon, a proprietary small molecule lead compound generated to selectively target and inactivate oncoproteins of the Myc family; and Xenomycin family of compounds, which have a range of potential applications as antimicrobial and anti-fungal agents. The company has license agreements and collaborations with the Cleveland Clinic, Roswell Park Cancer Institute, the Children's Cancer Institute Australia, and the Armed Forces Radiobiology Research Institute. Cleveland BioLabs, Inc. was founded in 2003 and is headquartered in Buffalo, New York.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Biology Solid Tumors Treatment Of Cancer Cancer Treatments Stem Cells Prostate Cancer Chemotherapy Radiation Coronavirus Carcinoma Cancer Treatment Novi Advanced Solid Tumors Hematopoietic Stem Cell Metastases Radiobiology Stage Products Liposome Chemotherapies Cleveland Clinic

Is CBLI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.9718
52 Week Low 1.43
Average Volume 324,901
200-Day Moving Average 3.68
50-Day Moving Average 6.12
20-Day Moving Average 5.69
10-Day Moving Average 5.81
Average True Range 0.61
ADX 18.73
+DI 23.25
-DI 27.51
Chandelier Exit (Long, 3 ATRs ) 5.33
Chandelier Exit (Short, 3 ATRs ) 6.42
Upper Bollinger Band 6.80
Lower Bollinger Band 4.58
Percent B (%b) 0.04
BandWidth 38.90
MACD Line -0.13
MACD Signal Line -0.01
MACD Histogram -0.1185
Fundamentals Value
Market Cap 60.79 Million
Num Shares 13 Million
EPS -0.27
Price-to-Earnings (P/E) Ratio -17.43
Price-to-Sales 57.64
Price-to-Book 0.00
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.31
Resistance 3 (R3) 5.36 5.18 5.21
Resistance 2 (R2) 5.18 5.02 5.16 5.17
Resistance 1 (R1) 4.93 4.92 4.84 4.88 5.14
Pivot Point 4.75 4.75 4.71 4.73 4.75
Support 1 (S1) 4.50 4.59 4.41 4.46 4.20
Support 2 (S2) 4.32 4.49 4.30 4.17
Support 3 (S3) 4.07 4.32 4.13
Support 4 (S4) 4.03